不同肽浓度下18F-PSMA-1007在小鼠前列腺癌中的摄取影响:临床前PET/CT研究
本研究利用LNCaP前列腺癌小鼠移植瘤模型,比较三种不同摩尔活度(MA)的18F-PSMA-1007注射液的全身分布。低MA组肿瘤SUVmean显著低于高MA组和中MA组,而唾液腺摄取下降幅度更大,导致肿瘤/唾液腺比值随MA降低而升高。免疫组化与Western blot证实肿瘤PSMA高表达而唾液腺和肾脏低表达。提示在PSMA靶向治疗中设定合适MA可能减轻唾液腺不良反应。
要点
- 低MA组肿瘤摄取显著低于高MA组和中MA组。
- 唾液腺摄取随MA降低下降幅度大于肿瘤,肿瘤/唾液腺比值升高。
- 肿瘤PSMA高表达而唾液腺低表达,提示可通过调节MA减轻唾液腺毒性。
核心结论
- 降低18F-PSMA-1007注射液的MA水平会导致肿瘤摄取下降,且唾液腺摄取下降程度更大。
- 通过设定合适的MA水平,有可能在PSMA靶向治疗中减轻唾液腺的不良反应。
研究设计与样本
- 采用LNCaP(PSMA阳性前列腺癌)小鼠移植瘤模型,共18只,按注射肽浓度分为高MA组(1,013 ± 146 GBq/μmol,n=6)、中MA组(100.7 ± 23.1 GBq/μmol,n=6)和低MA组(10.80 ± 2.84 GBq/μmol,n=6)。
- 注射后1小时进行10分钟静态PET扫描,比较肿瘤和正常器官的SUVmean;并行免疫组化染色和Western blot分析确认PSMA表达。
主要发现
- 低MA组肿瘤SUVmean为1.12 ± 0.30,显著低于高MA组(1.97 ± 0.77)和中MA组(1.81 ± 0.57)。
- 唾液腺中,低MA组SUVmean为0.24 ± 0.04,中MA组为0.57 ± 0.08,均显著低于高MA组(1.27 ± 0.28)。
- 肿瘤/唾液腺SUVmean比值在高MA组为1.73 ± 0.55,中MA组为3.16 ± 0.86,低MA组为4.78 ± 1.29。
- 免疫组化和Western blot显示肿瘤中PSMA显著过表达,而唾液腺和肾脏中低表达。
临床怎么用
- 在PSMA靶向诊疗中,需关注注射药物的MA水平对肿瘤和唾液腺摄取的影响。
- 调整MA可能作为减轻PSMA靶向治疗中唾液腺不良反应的策略,但需权衡肿瘤摄取下降。
局限性
- 本研究为小鼠临床前研究,结果外推至人体需进一步验证。
- 样本量较小(每组n=6),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET radioligands with low molar activity (MA) may underestimate the quantity of the target of interest because of competitive binding of the target with unlabeled ligand. The aim of this study was to evaluate the change in the whole-body distribution of 18F-PSMA-1007 targeting prostate-specific membrane antigen (PSMA) when solutions with different peptide concentrations are used. Methods: Mouse xenograft models of LNCaP (PSMA-positive prostate cancer) (n = 18) were prepared and divided into 3 groups according to the peptide concentration injected: a high-MA group (1,013 ± 146 GBq/μmol; n = 6), a medium-MA group (100.7 ± 23.1 GBq/μmol; n = 6), and a low-MA group (10.80 ± 2.84 GBq/μmol; n = 6). Static PET scans were performed 1 h after injection (scan duration, 10 min). SUVmean in tumor and normal organs was compared by the multiple-comparison test. Immunohistochemical staining and Western blot analysis were performed to confirm expression of PSMA in tumor, salivary gland, and kidney. Results: The low-MA group (SUVmean, 1.12 ± 0.30) showed significantly lower uptake of 18F-PSMA-1007 in tumor than did the high-MA group (1.97 ± 0.77) and the medium-MA group (1.81 ± 0.57). On the other hand, in salivary gland, both the low-MA group (SUVmean, 0.24 ± 0.04) and the medium-MA group (0.57 ± 0.08) showed significantly lower uptake than the high MA group (1.27 ± 0.28). The tumor-to-salivary gland SUVmean ratio was 1.73 ± 0.55 in the high-MA group, 3.16 ± 0.86 in the medium-MA group, and 4.78 ± 1.29 in the low-MA group. The immunohistochemical staining and Western blot analysis revealed significant overexpression of PSMA in tumor and low expression in salivary gland and kidney. Conclusion: A decrease in the MA level of the injected 18F-PSMA-1007 solution resulted in decreased uptake in tumor and, to a greater degree, in normal salivary gland. Thus, there is a possibility of minimizing the adverse effects in salivary gland by setting an appropriate MA level in PSMA-targeting therapy.
引用
- Soeda F, Watabe T, Naka S, et al. Impact of 18F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice. J Nucl Med. 2019. PMID: 30902876. doi:10.2967/jnumed.118.223479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。